Skip to content

Does Intralipid improve pregnancy outcomes in IVF? A Randomised Controlled Trial

Effect of administration of intravenous intralipid on implantation rate in women with implantation failure after IVF/ICSI with non-donor oocytes: A randomized controlled trial.

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/06/014451
Enrollment
100
Registered
2018-06-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Healthy women who have previous failed in vitro fertilisation

Interventions

Intervention1: Intralipid: 20% intralipid (Fresenius Kabi) diluted in 100 mL normal saline given in 2 doses in women with previous implantation failure, once on the day of oocyte pickup, and once on

Sponsors

All India Institute of Medical Sciences Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. History of one or more previously failed IVF/ICSI cycle. 2. Age 25 to 40 years 3. BMI in range of 20 to 32 4. Normal hormonal profile as assessed by DAY 2 FSH, LH, TSH, Prolactin, and AMH 5. Normal uterine cavity, as assessed by hysteroscopy or 3D ultrasonography. 6. Written consent to participate in trial

Exclusion criteria

Exclusion criteria: 1. Women with obvious anatomical causes for implantation failure like fibroids, abnormal hysteroscopy or ultrasonography findings 2. Donor oocyte IVF / ICSI 3. Age more than 40 years 4. Abnormal parental karyotype 5. BMI more than 27 6. Poor quality embryos as graded by SART morphological grade 7. Immunological and medical comorbidities like connective tissue disorders, diabetes, congenital or acquired blood dyscrasias 8. Clinical or laboratory findings of congenital or acquired thrombophilia. 9. Severe male factor infertility requiring surgical sperm retrievals. 10. Known history of allergic predisposition with known or possible allergy to soy products, lecithin , egg products 11. Mental illness which renders the patient unable to understand the nature of the trial

Design outcomes

Primary

MeasureTime frame
1. To measure and compare biochemical pregnancy rate per cycle of embryo transfer (serum beta HCG of100 IU) in women who receive intravenous intralipid prior to and on day of embryo transfer versus women who receive placebo 2. To assess and compare clinical pregnancy rate (USG shows fetal cardiac activity) in women who receive intravenous intralipid prior to and on day of embryo transfer versus women who receive placebo. Timepoint: 1. 16 days after embryo transfer 2. 6 weeks after embryo transfer

Secondary

MeasureTime frame
To measure and compare ongoing pregnancy rate and live birth rate in women who receive intravenous intralipid prior to and on day of embryo transfer versus women who receive placebo. Timepoint: 16 weeks of gestation

Countries

India

Contacts

Public ContactDr Amenda Ann Davis

All India Institute of Medical Sciences, Delhi

drneetasingh@yahoo.com011-26594251

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026